Investigational drug · Phase 2
Tigilanol Tiglate
Also called: EBC-46
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Soft Tissue Sarcoma, Head and Neck Cancer.
Phase 2Last checked: Nov 20, 2026Latest source record: Mar 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "Tigilanol Tiglate"
First trial start
2022
Nov 3, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Tigilanol Tiglate", any sponsor or status.
Conditions studied
As listed on its trial records.
- Soft Tissue Sarcoma
- Head and Neck Cancer
Approved drugs for the same conditions: Head and neck cancer · Sarcoma · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Tigilanol Tiglate" as an intervention, largest first.
QBiotics Group LimitedIndustry
NCT05755113 · 40 participants (planned) · Start Apr 13, 2023 · Primary completion Jan 2027
Drug: Tigilanol Tiglate · For: Soft Tissue Sarcoma
Sites: New York, New York
- A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck CancerActive, not recruiting
QBiotics Group LimitedIndustry
NCT05608876 · 15 participants · Start Nov 3, 2022 · Primary completion Jul 31, 2025
Drug: Tigilanol Tiglate · For: Head and Neck Cancer
Sites: Sydney, Australia; Brisbane, Australia; Cardiff, United Kingdom · 7 sites in all
- A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanomaTerminated
QBiotics Group LimitedIndustry
NCT04834973 · 3 participants · Start May 7, 2021 · Primary completion Jul 12, 2022
Drug: tigilanol tiglate; pembrolizumab · For: Melanoma
Sites: Wollstonecraft, Australia; Cairns, Australia
- A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c MelanomaTerminated
QBiotics Group LimitedIndustry
NCT05234437 · 1 participants · Start Mar 9, 2022 · Primary completion Jul 18, 2022
Drug: tigilanol tiglate · For: Melanoma
Sites: Wollstonecraft, Australia; Cairns, Australia; Woolloongabba, Australia
Newest research
PubMed records naming it or its code names, newest first.
- Proof of Concept for Open Flow Microperfusion for Intratumoural Drug Administration in Equine Cutaneous Neoplasia.
Labens R, Reddell P, Birngruber T · Animals (Basel) 2026
- Proof of concept for low dose and delayed release of tigilanol tiglate in the treatment of equine sarcoids.
Stemmet GP, Parsons P, Johns J, et al. · Front Vet Sci 2026
- Case Report: Severe wound formation following intratumoral tigilanol tiglate treatment resulting in limb amputation in a 10-year-old male dog.
Kitson L, Runge JJ, Shay M · Front Vet Sci 2026
- Intratumoural tigilanol tiglate in the multicentre treatment of equine sarcoids and cutaneous melanomas.
Labens R, Saba C, Williams J, et al. · Equine Vet J 2026
- Synthesis and preclinical evaluation of tigilanol tiglate analogs as latency-reversing agents for the eradication of HIV.
Gentry ZO, McAteer OD, Hamad JL, et al. · Sci Adv 2025
- Epoxytiglianes induce keratinocyte wound healing responses via classical protein kinase C activation to promote skin re-epithelialization.
Moses RL, Woods EL, Dally J, et al. · Biochem Pharmacol 2024
Also in development for Soft Tissue Sarcoma
- L19TNFL19IL2, OnfekafuspPhase 310 trials
Philogen S.p.A. · Glioblastoma, Locally Advanced Basal Cell Carcinoma, Melanoma Stage III
- ChiauranibCS2164Phase 33 trials
Chipscreen Biosciences, Ltd. · Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Soft Tissue Sarcoma
- 1.0% IP-001IP-001Phase 32 trials
Immunophotonics, Inc. · Colorectal Cancer (CRC), Colon Cancer Liver Metastases, Rectal Cancer
- TQB2916Phase 22 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Soft Tissue Sarcoma, Melanoma, Pancreatic Cancer
- CYT-0851Phase 21 trial
Cyteir Therapeutics, Inc. · Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.